Deborah Grady
is Professor of Epidemiology and of Medicine and Vice Chair of the Department of Epidemiology in the School of Medicine at UCSF. Dr. Grady is a general internist who provides clinical care for adult women. She is an international expert on the risks and benefits of postmenopausal hormone therapy and has published extensively on this topic. She was author of the 1992 evidence-based guidelines for use of postmenopausal hormone therapy of the American College of Physicians which were also adopted by the American College of Family Practice and the US Preventive Services Task Force. Dr. Grady currently directs the UCSF/Mt. Zion Women's Health Clinical Research Center and Clinical Research Fellowship. Dr. Grady also serves as Program Director for the UCSF Women's Health Interdisciplinary Scholarship Program in Research, a NIH-funded program to support junior faculty training in clinical research in women's health. Dr. Grady is Associate Director of the UCSF Training in Clinical Research Program (TICR) and director of the Systematic Reviews and Clinical Trials courses in TICR. Dr. Grady is a respected methodologist and one of the editors of Designing Clinical Research, a widely used textbook on clinical research methods. Dr. Grady is specifically interested in the design and conduct of clinical trials, having led several of the largest clinical trials in women's health ever completed, including the Heart and Estrogen/progestin Replacement Study (N = 2763) and the Raloxifene Use for the Heart (N=10,101). Dr. Grady is currently PI of a 9-center trial of the effect of ultra low-dose transdermal estrogen on bone density and uterine health (ULTRA) and PI of an AHRQ-funded project to review and synthesize the medical literature related to coronary disease in women. She is co-PI of the coordinating center for extended follow-up of women enrolled in the Heart and Estrogen/progestin Replacement Study, a 20-center clinical trial of the effect of estrogen plus progestin on coronary events. Dr. Grady serves on the Executive Committee for the 159-center international trial of the effect of raloxifene on coronary events (Raloxifene Use for the Heart) and is a member of the Governing Board of the UCSF-Stanford Evidence Based Practice Center.
|
![[California]](/stanford-ucsf-epc/images/epc-logo.jpg){kind=logo}
Members Page